ZDA
EVH icon

Zweig-DiMenna Associates’s Evolent Health EVH Stock Holding History

Zweig-DiMenna Associates’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,470
Closed -$369K – 181
2021
Q2 		$369K Buy
+17,470
New +$350K 0.02% 189

Other funds holding EVH

EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Zweig-DiMenna Associates's EVH Position: Q3 2021 in Review

Zweig-DiMenna Associates sold out of Evolent Health (EVH) in Q3 2021, closing a stake of 17,470 shares — an estimated $369K sold.

Zweig-DiMenna Associates first reported a position in EVH in Q2 2021 and held it in 1 quarter. The position peaked at $369K in Q2 2021. 209 funds tracked by Wall St. Rank hold EVH as of Q3 2021.

  • Zweig-DiMenna Associates reported no remaining Evolent Health position as of Q3 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 17,470 Evolent Health shares in Q3 2021, an estimated $369K.
  • Zweig-DiMenna Associates first reported a position in Evolent Health in Q2 2021 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Evolent Health position peaked at $369K in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Evolent Health as of Q3 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2021, filed 25 Oct 2021.